MetfoRmin and its Effects on Myocardial Dimension and Left Ventricular Hypertrophy in Normotensive Patients with Coronary Artery Disease (MET-REMODEL Trial)

Medicine & Life Sciences

1. Metformin 100%
2. Coronary Artery Disease 53%
3. Ventricular Remodeling 44%
4. Left Ventricular Hypertrophy 42%
5. 2-(3-(4-ethoxybenzyl)-4-chlorophenyl)-6-hydroxymethyltetrahydro-2H-pyran-3,4,5-triol 38%
6. Heart Failure 30%
7. Symporters 25%
8. Placebos 24%
9. Aortic Valve Stenosis 20%
10. Coronary Disease 16%
11. Adipose Tissue 15%
12. Sodium 15%
13. Insulin Resistance 15%
14. Diabetes Mellitus 14%
15. Randomized Controlled Trials 13%
16. Anti-Inflammatory Agents 13%
17. Homeostasis 13%
18. Amino Acids 13%
19. Glucose 13%
20. Blood Pressure 13%
21. Branched Chain Amino Acids 12%
22. BI605906 9%
23. Cardiovascular Diseases 9%
24. Stroke Volume 9%
25. Alleles 6%
26. Therapeutics 5%
27. Type 2 Diabetes Mellitus 5%
28. Sodium Potassium Chloride Symporter Inhibitors 5%